Company: ADPT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001193125-25-267061
Chunk: 14

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 8
Chunk 14
---
ability and impairment of long-lived assets, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.Unaudited Interim Condensed Consolidated Financial StatementsIn our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025.Restricted CashWe had a restricted cash balance of $2.7 million and $2.9 million as of September 30, 2025 and December 31, 2024, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our facility leases.